https://www.thebodypro.com/category/first-line-hiv-treatment/tag/conference-coverage
First-Line HIV Treatment

Conference Coverage

The Latest

Promo Image

Initial HIV Treatment With a 2-Drug, Nuke-Sparing Regimen Falls Short

For many years, we've wondered about the long-term safety of nucleoside/tide reverse transcriptase inhibitors (NRTIs). Our sometimes-lethal experiences with dideoxynucleosides cemented this sentiment, one that lingers today, even with far better nuke...

Promo Image

Raltegravir Superior to Boosted Protease Inhibitors as First-Line Treatment

U.S. treatment guidelines equally recommend first-line treatment regimens that include either a non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (Sustiva, Stocrin); one of two ritonavir (Norvir)-boosted protease inhibitors (PIs), ata...

Promo Image

Very Early Treatment Benefits and Possible HIV Eradication

From the "Berlin Patient" to the "Mississippi Baby," we're gaining an appreciation for the possible benefits and utility of very early antiretroviral therapy (ART). Several studies at CROI 2014 explored this subject. In a study of HIV infection using...

In Battle of First-Line HIV Drugs, Raltegravir Beats Two Protease Inhibitors Img

In Battle of First-Line HIV Drugs, Raltegravir Beats Two Protease Inhibitors

A major, head-to-head comparison of three common HIV medications finds that all three are very good. But subtle differences set each of them apart from the others.

Early Treatment and Weight Management May Prevent Common Comorbidities in Young People Living With HIV Img

Early Treatment and Weight Management May Prevent Common Comorbidities in Young People Living With HIV

Newly diagnosed people often have two or more additional health problems, such as depression, high cholesterol or high blood pressure. But research shows all of these issues can be tackled alongside HIV.

HIV Rebound Risk May Be Predicted by Baseline Viral Load, Time to Viral Suppression Img

HIV Rebound Risk May Be Predicted by Baseline Viral Load, Time to Viral Suppression

A person's viral load when he or she first starts HIV medications may at least partly predict his or her chances of long-term treatment success, according to a recent study.

Why Patients (and Their Doctors) Choose Not to Start HIV Treatment Img

Why Patients (and Their Doctors) Choose Not to Start HIV Treatment

Think the main reasons why people avoid HIV meds are related to a fear of side effects? Aversion to taking pills every day? Adherence concerns? Guess again: A new study pushes back against those long-held assumptions.

Promo Image

Study Cites Benefits of Early AIDS Treatment

Starting antiretroviral therapy (ART) earlier rather than later is cost-effective and helps prevent AIDS-related illnesses, according to two studies presented at the 19th International AIDS Conference in Washington. The studies add to a body of evide...

Promo Image

Expanded Analysis of HPTN 052 Study Results Reveal Additional Benefits of Early HIV Treatment

Study results released today by the HIV Prevention Trials Network (HPTN) show additional benefits of early antiretroviral therapy (ART) in HIV clinical outcomes. Expanded analysis of HPTN 052 study data, presented today at the XIX International AIDS ...

Promo Image

When to Start ART in Patients Co-Infected With TB: Results From Two Trials Presented at CROI

Table of Contents

Introduction Stride SAPIT Comment References

Introduction

The complex question of the optimal time to start antiretroviral therapy (ART) in HIV-positive patients co-infected with TB was the subject of two important presen...